What is the projected market valuation for the Opioid Induced Constipation Drug Market in 2035?

The projected market valuation for the Opioid Induced Constipation Drug Market in 2035 is 3.307 USD Billion. Read More

What was the market valuation for the Opioid Induced Constipation Drug Market in 2024?

The market valuation for the Opioid Induced Constipation Drug Market in 2024 was 1.897 USD Billion. Read More

What is the expected CAGR for the Opioid Induced Constipation Drug Market from 2025 to 2035?

The expected CAGR for the Opioid Induced Constipation Drug Market during the forecast period 2025 - 2035 is 5.18%. Read More

Which companies are key players in the Opioid Induced Constipation Drug Market?

Key players in the market include Boehringer Ingelheim, Takeda Pharmaceutical Company Limited, AstraZeneca, Mallinckrodt Pharmaceuticals, Pfizer Inc., Sorrento Therapeutics, Salix Pharmaceuticals, and NantKwest. Read More

How much is the Opioid-Induced Constipation segment valued at in 2024?

The Opioid-Induced Constipation segment was valued at 1.2 USD Billion in 2024. Read More

What is the valuation of the Antagonists segment in the Opioid Induced Constipation Drug Market?

The Antagonists segment is valued at 0.38 USD Billion in 2024 and is projected to reach 0.654 USD Billion by 2035. Read More

What routes of administration are available for drugs treating Opioid Induced Constipation?

Available routes of administration include Oral, Rectal, and Intravenous. Read More

What is the projected growth for the Peripherally Acting Opioid Receptor Antagonists segment by 2035?

The Peripherally Acting Opioid Receptor Antagonists segment is projected to grow from 0.759 USD Billion in 2024 to 1.327 USD Billion by 2035. Read More

How does the market for Non-Opioid-Induced Constipation compare to Opioid-Induced Constipation?

The Non-Opioid-Induced Constipation segment was valued at 0.697 USD Billion in 2024, compared to 1.2 USD Billion for Opioid-Induced Constipation. Read More

Opioid Induced Constipation Drug Market

Q: What are the main drug classes in the Opioid Induced Constipation Drug Market?

The main drug classes include Peripherally Acting Opioid Receptor Antagonists, Peripherally Acting Non-Opioid Receptor Agonists, Centrally Acting Laxatives, and Osmotic Laxatives. Read More

ID: MRFR/HC/32071-HCR

128 Pages

Rahul Gotadki

Last Updated: April 24, 2026

Opioid Induced Constipation Drug Market Research Report By Opioid Type (Agonists, Partial Agonists, Mixed Agonists/Antagonists, Antagonists), By Drug Class (Peripherally Acting -Opioid Receptor Antagonists, Peripherally Acting Non-Opioid Receptor Agonists, Centrally Acting Laxatives, Osmotic Laxatives), By Route of Administration (Oral, Rectal, Intravenous), By Indication (Opioid-Induced Constipation, Non-Opioid-Induced Constipation) and By Regional (North America, Europe, South America, Asia-Pacific, Middle East and Africa) - Forecast to 2035

Opioid Induced Constipation Drug Market Infographic

Summary Table of Contents Segmentation Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Opioid Type (USD Billion) | |
  1. 4.1.1 Agonists | |
  2. 4.1.2 Partial Agonists | |
  3. 4.1.3 Mixed Agonists/Antagonists | |
  4. 4.1.4 Antagonists |
2. 4.2 Healthcare, BY Drug Class (USD Billion) | |
  1. 4.2.1 Peripherally Acting Opioid Receptor Antagonists | |
  2. 4.2.2 Peripherally Acting Non-Opioid Receptor Agonists | |
  3. 4.2.3 Centrally Acting Laxatives | |
  4. 4.2.4 Osmotic Laxatives |
3. 4.3 Healthcare, BY Route of Administration (USD Billion) | |
  1. 4.3.1 Oral | |
  2. 4.3.2 Rectal | |
  3. 4.3.3 Intravenous |
4. 4.4 Healthcare, BY Indication (USD Billion) | |
  1. 4.4.1 Opioid-Induced Constipation | |
  2. 4.4.2 Non-Opioid-Induced Constipation |
5. 4.5 Healthcare, BY Region (USD Billion) | |
  1. 4.5.1 North America | | |
    1. 4.5.1.1 US | | |
    2. 4.5.1.2 Canada | |
  2. 4.5.2 Europe | | |
    1. 4.5.2.1 Germany | | |
    2. 4.5.2.2 UK | | |
    3. 4.5.2.3 France | | |
    4. 4.5.2.4 Russia | | |
    5. 4.5.2.5 Italy | | |
    6. 4.5.2.6 Spain | | |
    7. 4.5.2.7 Rest of Europe | |
  3. 4.5.3 APAC | | |
    1. 4.5.3.1 China | | |
    2. 4.5.3.2 India | | |
    3. 4.5.3.3 Japan | | |
    4. 4.5.3.4 South Korea | | |
    5. 4.5.3.5 Malaysia | | |
    6. 4.5.3.6 Thailand | | |
    7. 4.5.3.7 Indonesia | | |
    8. 4.5.3.8 Rest of APAC | |
  4. 4.5.4 South America | | |
    1. 4.5.4.1 Brazil | | |
    2. 4.5.4.2 Mexico | | |
    3. 4.5.4.3 Argentina | | |
    4. 4.5.4.4 Rest of South America | |
  5. 4.5.5 MEA | | |
    1. 4.5.5.1 GCC Countries | | |
    2. 4.5.5.2 South Africa | | |
    3. 4.5.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Boehringer Ingelheim (DE) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Takeda Pharmaceutical Company Limited (JP) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 AstraZeneca (GB) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Mallinckrodt Pharmaceuticals (IE) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Pfizer Inc. (US) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Sorrento Therapeutics (US) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Salix Pharmaceuticals (US) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 NantKwest (US) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY OPIOID TYPE |
7. 6.4 US MARKET ANALYSIS BY DRUG CLASS |
8. 6.5 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
9. 6.6 US MARKET ANALYSIS BY INDICATION |
10. 6.7 CANADA MARKET ANALYSIS BY OPIOID TYPE |
11. 6.8 CANADA MARKET ANALYSIS BY DRUG CLASS |
12. 6.9 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
13. 6.10 CANADA MARKET ANALYSIS BY INDICATION |
14. 6.11 EUROPE MARKET ANALYSIS |
15. 6.12 GERMANY MARKET ANALYSIS BY OPIOID TYPE |
16. 6.13 GERMANY MARKET ANALYSIS BY DRUG CLASS |
17. 6.14 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
18. 6.15 GERMANY MARKET ANALYSIS BY INDICATION |
19. 6.16 UK MARKET ANALYSIS BY OPIOID TYPE |
20. 6.17 UK MARKET ANALYSIS BY DRUG CLASS |
21. 6.18 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
22. 6.19 UK MARKET ANALYSIS BY INDICATION |
23. 6.20 FRANCE MARKET ANALYSIS BY OPIOID TYPE |
24. 6.21 FRANCE MARKET ANALYSIS BY DRUG CLASS |
25. 6.22 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
26. 6.23 FRANCE MARKET ANALYSIS BY INDICATION |
27. 6.24 RUSSIA MARKET ANALYSIS BY OPIOID TYPE |
28. 6.25 RUSSIA MARKET ANALYSIS BY DRUG CLASS |
29. 6.26 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
30. 6.27 RUSSIA MARKET ANALYSIS BY INDICATION |
31. 6.28 ITALY MARKET ANALYSIS BY OPIOID TYPE |
32. 6.29 ITALY MARKET ANALYSIS BY DRUG CLASS |
33. 6.30 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
34. 6.31 ITALY MARKET ANALYSIS BY INDICATION |
35. 6.32 SPAIN MARKET ANALYSIS BY OPIOID TYPE |
36. 6.33 SPAIN MARKET ANALYSIS BY DRUG CLASS |
37. 6.34 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
38. 6.35 SPAIN MARKET ANALYSIS BY INDICATION |
39. 6.36 REST OF EUROPE MARKET ANALYSIS BY OPIOID TYPE |
40. 6.37 REST OF EUROPE MARKET ANALYSIS BY DRUG CLASS |
41. 6.38 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
42. 6.39 REST OF EUROPE MARKET ANALYSIS BY INDICATION |
43. 6.40 APAC MARKET ANALYSIS |
44. 6.41 CHINA MARKET ANALYSIS BY OPIOID TYPE |
45. 6.42 CHINA MARKET ANALYSIS BY DRUG CLASS |
46. 6.43 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
47. 6.44 CHINA MARKET ANALYSIS BY INDICATION |
48. 6.45 INDIA MARKET ANALYSIS BY OPIOID TYPE |
49. 6.46 INDIA MARKET ANALYSIS BY DRUG CLASS |
50. 6.47 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
51. 6.48 INDIA MARKET ANALYSIS BY INDICATION |
52. 6.49 JAPAN MARKET ANALYSIS BY OPIOID TYPE |
53. 6.50 JAPAN MARKET ANALYSIS BY DRUG CLASS |
54. 6.51 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
55. 6.52 JAPAN MARKET ANALYSIS BY INDICATION |
56. 6.53 SOUTH KOREA MARKET ANALYSIS BY OPIOID TYPE |
57. 6.54 SOUTH KOREA MARKET ANALYSIS BY DRUG CLASS |
58. 6.55 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
59. 6.56 SOUTH KOREA MARKET ANALYSIS BY INDICATION |
60. 6.57 MALAYSIA MARKET ANALYSIS BY OPIOID TYPE |
61. 6.58 MALAYSIA MARKET ANALYSIS BY DRUG CLASS |
62. 6.59 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
63. 6.60 MALAYSIA MARKET ANALYSIS BY INDICATION |
64. 6.61 THAILAND MARKET ANALYSIS BY OPIOID TYPE |
65. 6.62 THAILAND MARKET ANALYSIS BY DRUG CLASS |
66. 6.63 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
67. 6.64 THAILAND MARKET ANALYSIS BY INDICATION |
68. 6.65 INDONESIA MARKET ANALYSIS BY OPIOID TYPE |
69. 6.66 INDONESIA MARKET ANALYSIS BY DRUG CLASS |
70. 6.67 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
71. 6.68 INDONESIA MARKET ANALYSIS BY INDICATION |
72. 6.69 REST OF APAC MARKET ANALYSIS BY OPIOID TYPE |
73. 6.70 REST OF APAC MARKET ANALYSIS BY DRUG CLASS |
74. 6.71 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
75. 6.72 REST OF APAC MARKET ANALYSIS BY INDICATION |
76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
77. 6.74 BRAZIL MARKET ANALYSIS BY OPIOID TYPE |
78. 6.75 BRAZIL MARKET ANALYSIS BY DRUG CLASS |
79. 6.76 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
80. 6.77 BRAZIL MARKET ANALYSIS BY INDICATION |
81. 6.78 MEXICO MARKET ANALYSIS BY OPIOID TYPE |
82. 6.79 MEXICO MARKET ANALYSIS BY DRUG CLASS |
83. 6.80 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
84. 6.81 MEXICO MARKET ANALYSIS BY INDICATION |
85. 6.82 ARGENTINA MARKET ANALYSIS BY OPIOID TYPE |
86. 6.83 ARGENTINA MARKET ANALYSIS BY DRUG CLASS |
87. 6.84 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
88. 6.85 ARGENTINA MARKET ANALYSIS BY INDICATION |
89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY OPIOID TYPE |
90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY DRUG CLASS |
91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY INDICATION |
93. 6.90 MEA MARKET ANALYSIS |
94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY OPIOID TYPE |
95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY DRUG CLASS |
96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY INDICATION |
98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY OPIOID TYPE |
99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY DRUG CLASS |
100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY INDICATION |
102. 6.99 REST OF MEA MARKET ANALYSIS BY OPIOID TYPE |
103. 6.100 REST OF MEA MARKET ANALYSIS BY DRUG CLASS |
104. 6.101 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
105. 6.102 REST OF MEA MARKET ANALYSIS BY INDICATION |
106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
107. 6.104 RESEARCH PROCESS OF MRFR |
108. 6.105 DRO ANALYSIS OF HEALTHCARE |
109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
112. 6.109 HEALTHCARE, BY OPIOID TYPE, 2024 (% SHARE) |
113. 6.110 HEALTHCARE, BY OPIOID TYPE, 2024 TO 2035 (USD Billion) |
114. 6.111 HEALTHCARE, BY DRUG CLASS, 2024 (% SHARE) |
115. 6.112 HEALTHCARE, BY DRUG CLASS, 2024 TO 2035 (USD Billion) |
116. 6.113 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE) |
117. 6.114 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion) |
118. 6.115 HEALTHCARE, BY INDICATION, 2024 (% SHARE) |
119. 6.116 HEALTHCARE, BY INDICATION, 2024 TO 2035 (USD Billion) |
120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
121. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY OPIOID TYPE, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY INDICATION, 2025-2035 (USD Billion) |
123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY OPIOID TYPE, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.3.4 BY INDICATION, 2025-2035 (USD Billion) |
124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY OPIOID TYPE, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.4.4 BY INDICATION, 2025-2035 (USD Billion) |
125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY OPIOID TYPE, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.5.4 BY INDICATION, 2025-2035 (USD Billion) |
126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY OPIOID TYPE, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.6.4 BY INDICATION, 2025-2035 (USD Billion) |
127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY OPIOID TYPE, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.7.4 BY INDICATION, 2025-2035 (USD Billion) |
128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY OPIOID TYPE, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.8.4 BY INDICATION, 2025-2035 (USD Billion) |
129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY OPIOID TYPE, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.9.4 BY INDICATION, 2025-2035 (USD Billion) |
130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY OPIOID TYPE, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.10.4 BY INDICATION, 2025-2035 (USD Billion) |
131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY OPIOID TYPE, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.11.4 BY INDICATION, 2025-2035 (USD Billion) |
132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY OPIOID TYPE, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.12.4 BY INDICATION, 2025-2035 (USD Billion) |
133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY OPIOID TYPE, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.13.4 BY INDICATION, 2025-2035 (USD Billion) |
134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY OPIOID TYPE, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.14.4 BY INDICATION, 2025-2035 (USD Billion) |
135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY OPIOID TYPE, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.15.4 BY INDICATION, 2025-2035 (USD Billion) |
136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY OPIOID TYPE, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.16.4 BY INDICATION, 2025-2035 (USD Billion) |
137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY OPIOID TYPE, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.17.4 BY INDICATION, 2025-2035 (USD Billion) |
138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY OPIOID TYPE, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.18.4 BY INDICATION, 2025-2035 (USD Billion) |
139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY OPIOID TYPE, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.19.4 BY INDICATION, 2025-2035 (USD Billion) |
140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY OPIOID TYPE, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.20.4 BY INDICATION, 2025-2035 (USD Billion) |
141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY OPIOID TYPE, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.21.4 BY INDICATION, 2025-2035 (USD Billion) |
142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY OPIOID TYPE, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.22.4 BY INDICATION, 2025-2035 (USD Billion) |
143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY OPIOID TYPE, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.23.4 BY INDICATION, 2025-2035 (USD Billion) |
144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY OPIOID TYPE, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.24.4 BY INDICATION, 2025-2035 (USD Billion) |
145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY OPIOID TYPE, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.25.4 BY INDICATION, 2025-2035 (USD Billion) |
146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY OPIOID TYPE, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.26.4 BY INDICATION, 2025-2035 (USD Billion) |
147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY OPIOID TYPE, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.27.4 BY INDICATION, 2025-2035 (USD Billion) |
148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY OPIOID TYPE, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.28.4 BY INDICATION, 2025-2035 (USD Billion) |
149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY OPIOID TYPE, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.29.4 BY INDICATION, 2025-2035 (USD Billion) |
150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY OPIOID TYPE, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.30.4 BY INDICATION, 2025-2035 (USD Billion) |
151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
152. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Opioid Type (USD Billion, 2025-2035)

Agonists
Partial Agonists
Mixed Agonists/Antagonists
Antagonists

Healthcare By Drug Class (USD Billion, 2025-2035)

Peripherally Acting Opioid Receptor Antagonists
Peripherally Acting Non-Opioid Receptor Agonists
Centrally Acting Laxatives
Osmotic Laxatives

Healthcare By Route of Administration (USD Billion, 2025-2035)

Oral
Rectal
Intravenous

Healthcare By Indication (USD Billion, 2025-2035)

Opioid-Induced Constipation
Non-Opioid-Induced Constipation

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓